The most recent
On Thursday, U.S. FDA advisers voted for the Moderna Inc. vaccine. COVID-19 mRNA.
20 votes against 0, by one voter, was even more certain than the 17 votes against 4 for BioNTech / Pfizer Inc. support. vaccine.
Some concerns about the administration of Pfizer Inc. The vaccine for 16-18 year olds had resulted in all 4 votes against.
On the other hand, the Moderna Inc. the vaccine is for people aged 18 or over, reducing concerns about the effects of the vaccine on younger age groups.
In response to the review, the FDA announced its intention to approve EUA Moderna Inc. too later today.
What now?
Once the EUA is approved by the FDA, Moderna Inc. expects to deliver 20 million doses to the U.S. by the end of the month. That’s enough to vaccinate 10 million in the US An additional 80 million are then delivered by the 1st quarter and 100 million more in the 2nd quarter.
In line with CDC priorities, the first batch would cover a large proportion of stage 1a recipients.
With the number of new COVID-19 cases steadily rising alongside death taxes, there will be a crisis.
Compared to the Pfizer Inc. vaccination, transportation and distribution Moderna Inc. the vaccine is less severe.
Conveying the vaccine in a thawing state at normal cooling temperature can be considered. This will mean Moderna Inc. it is likely to be delivered to key areas much more quickly over the next week.
Moderna Inc. we need to avoid supply chain issues and production capacity to deliver the 20 million doses.
The latest COVID-19 numbers
At the time of writing, the total number of confirmed COVID-19 cases was 75,283,501. The total number of U.S. cases has risen to 17,627,030, with the total number of related deaths rising to 317,929.
Things are still terrible in other parts of the world, with new issues continuing to decline during the winter months.
Moderna Inc. vaccine. coming in times of crisis. More consent for vaccines, however, will be needed to prevent the spread of the virus.